X4 Pharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc. in brief
X4 Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. It was founded in 2010. Its market value was $332 M on 28 October 2026, which makes it the 14,362nd largest listed company in the world and the 2,811th largest in the USA on this site. In the year to December 2025 it had sales of $35 M and a net loss of $79 M. It employs about 45 people. Its largest product and service lines by sales in 2025 were License and other revenue (81%). Its shares trade under the symbol XFOR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About X4 Pharmaceuticals, Inc.
We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners.
Our primary asset is mavorixafor, a small molecule delivered in a capsule for oral dosing as a selective antagonist of the chemokine receptor, CXCR4. We have one commercially approved product, XOLREMDI® (mavorixafor), which has received accelerated approval in the United States from the FDA for use as an oral, once-daily therapy in patients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, to increase the number of circulating mature neutrophils and lymphocytes. WHIM syndrome is a rare combined primary immunodeficiency and chronic neutropenic disorder. Mavorixafor is currently being studied in a pivotal clinical trial in chronic neutropenia.
From the company's annual report filed with the US SEC: read the report
X4 Pharmaceuticals, Inc. timeline
- 2010
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offering as Arsanis, Inc.Final prospectus filed with the SEC on 17 November 2017; shares registered for exchange trading on 15 November 2017.
- 2019
- ✎Renamed X4 Pharmaceuticals, IncFormerly Arsanis, Inc..
- 2025
- 💰Record revenue of $35 millionFY2025, the highest of the 3 years on record.
Events of X4 Pharmaceuticals, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,510 (Jan 2020) · #3,662 (Jan 2021) · #4,776 (Jan 2022) · #4,244 (Dec 2022) · #3,270 (Jul 2023) · #3,486 (Jan 2024) · #1,466 (Mar 2026) · #2,637 (Aug 2026) · #2,815 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 9.5×
- Price / book
- 1.8×
- Free cash flow yield
- -25.8%
- Net margin
- -225.6%
- Operating margin
- -247.5%
- Return on equity
- -42.5%
- Liabilities / assets
- 35.9%
- Net debt
- $-142M
- Revenue growth
- +1250.4%
- R&D / revenue
- 207.1%
- Revenue per employee
- $780 K
- Profit per employee
- $-1.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $35M | +1250.4% | $-87M | $-79M | -225.6% |
| Dec 2024 | $3M | — | $-36M | $-37M | -1440.4% |
| Dec 2023 | — | — | $-108M | $-101M | — |
| Dec 2022 | — | — | $-88M | $-94M | — |
| Dec 2021 | — | — | $-85M | $-89M | — |
| Dec 2020 | $3M | — | $-60M | $-62M | -2071.0% |
| Dec 2019 | — | — | $-52M | $-53M | — |
| Dec 2018 | — | — | $-29M | $-33M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-86M | $0M | $-86M | $-1.87 | — |
| Dec 2024 | $-131M | $0M | $-131M | $-5.59 | — |
| Dec 2023 | $-97M | $0M | $-97M | $-17.07 | — |
| Dec 2022 | $-77M | $0M | $-77M | $-1.52 | — |
| Dec 2021 | $-71M | $1M | $-72M | $-3.99 | — |
| Dec 2020 | $-59M | $1M | $-60M | $-3.09 | — |
| Dec 2019 | $-48M | $0M | $-48M | $-4.63 | — |
| Dec 2018 | $-25M | $0M | $-25M | $-79.15 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $3M (+75.0% on a year earlier), net income $-20M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Oct 29, 20268-KCurrent reportOther events
- Oct 8, 20268-KCurrent reportMaterial agreement · Agreement ended · New financial obligation · Unregistered share sale · Regulation FD disclosure
- Sep 9, 20268-KCurrent reportOther events
- Sep 8, 20268-KCurrent reportOther events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jul 1, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- May 13, 20268-K/ACurrent report (amended)Directors or officers changed · Shareholder vote
- May 12, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 6, 202610-QQuarterly report · period to Mar 2026
- Mar 20, 2026DEF 14AProxy statement
- Mar 17, 202610-KAnnual report · period to Dec 2025
Official filings of X4 Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $35 M
- Operating income
- $-87 M
- Net income
- $-79 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $290 M
- Total liabilities
- $104 M
- Total equity
- $186 M
As of December-2025
Top 96 institutional investors in X4 Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Morgan Stanley | 10,996,210 | +1,534,931 (+16.22%) | 10.77% | $32 M | Nov 13, 2026 |
| 2 | Empery Asset Management, LP | 9,725,509 | +2,794,918 (+40.33%) | 9.52% | $28 M | Nov 16, 2026 |
| 3 | Bain Capital Life Sciences Investors, LLC | 7,967,454 | 0 (0.00%) | 7.80% | $23 M | Nov 16, 2026 |
| 4 | Venrock Adviser, LLC | 7,644,072 | +5,709,819 (+295.20%) | 7.49% | $22 M | Nov 16, 2026 |
| 5 | Saturn V Capital Management LP | 7,366,442 | +393,099 (+5.64%) | 7.21% | $21 M | Nov 16, 2026 |
| 6 | Perceptive Advisors LLC | 7,350,491 | -583,000 (-7.35%) | 7.20% | $21 M | Nov 16, 2026 |
| 7 | BlackRock, Inc. | 5,854,521 | +299,615 (+5.39%) | 5.73% | $17 M | Nov 13, 2026 |
| 8 | FMR LLC | 5,490,787 | -2,830,870 (-34.02%) | 5.38% | $16 M | Nov 10, 2026 |
| 9 | Deep Track Capital, LP | 4,501,684 | -1,377,073 (-23.42%) | 4.41% | $13 M | Nov 16, 2026 |
| 10 | Kalehua Capital Management LLC | 3,722,840 | -3,722,840 (-50.00%) | 3.65% | $11 M | Nov 13, 2026 |
| 11 | Vanguard Capital Management LLC | 3,558,591 | -157,268 (-4.23%) | 3.48% | $10 M | Nov 13, 2026 |
| 12 | Rosalind Advisors, Inc. | 3,214,766 | 0 (0.00%) | 3.15% | $9 M | Nov 16, 2026 |
| 13 | Trails Edge Capital Partners, LP | 2,571,478 | 0 (0.00%) | 2.52% | $7 M | Nov 16, 2026 |
| 14 | Nantahala Capital Management, LLC | 2,449,468 | -2,449,468 (-50.00%) | 2.40% | $7 M | Nov 13, 2026 |
| 15 | Blackstone Inc. | 2,427,080 | -254,842 (-9.50%) | 2.38% | $7 M | Nov 16, 2026 |
| 16 | Braidwell LP | 2,344,822 | -577,932 (-19.77%) | 2.30% | $7 M | Nov 16, 2026 |
| 17 | Goldman Sachs Group Inc | 2,335,042 | +1,418,506 (+154.77%) | 2.29% | $7 M | Nov 16, 2026 |
| 18 | Affinity Asset Advisors, LLC | 2,062,500 | +1,917,500 (+1322.41%) | 2.02% | $6 M | Nov 13, 2026 |
| 19 | Geode Capital Management, LLC | 2,047,281 | -50,766 (-2.42%) | 2.00% | $6 M | Nov 6, 2026 |
| 20 | State Street Corp | 1,730,123 | +434,106 (+33.50%) | 1.69% | $5 M | Nov 12, 2026 |
| 21 | BVF Inc/il | 1,576,624 | -657,118 (-29.42%) | 1.54% | $5 M | Nov 16, 2026 |
| 22 | Samsara Biocapital, LLC | 1,347,723 | -47,864 (-3.43%) | 1.32% | $4 M | Nov 16, 2026 |
| 23 | Woodline Partners LP | 1,001,095 | 0 (0.00%) | 0.98% | $3 M | Nov 16, 2026 |
| 24 | Northern Trust Corp | 627,744 | -25,105 (-3.85%) | 0.61% | $2 M | Nov 16, 2026 |
| 25 | Vanguard Portfolio Management LLC | 572,106 | +29,978 (+5.53%) | 0.56% | $2 M | Nov 13, 2026 |
Show all 96: investors 26 to 96
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Fiduciary Trust Co | 512,811 | -59,227 (-10.35%) | 0.50% | $1 M | Nov 13, 2026 |
| 27 | Verdad Advisers, LP | 323,166 | -28,927 (-8.22%) | 0.32% | $1 M | Nov 16, 2026 |
| 28 | Wellington Management Group LLP | 289,231 | +237,431 (+458.36%) | 0.28% | $1 M | Nov 16, 2026 |
| 29 | Charles Schwab Investment Management Inc | 263,282 | +18 (+0.01%) | 0.26% | $1 M | Nov 16, 2026 |
| 30 | Integral Health Asset Management, LLC | 250,000 | New | 0.24% | $1 M | Nov 16, 2026 |
| 31 | Russell Investments Group, Ltd. | 213,258 | +206,080 (+2870.99%) | 0.21% | $1 M | Nov 6, 2026 |
| 32 | Bank of New York Mellon Corp | 204,991 | +8,651 (+4.41%) | 0.20% | $1 M | Nov 5, 2026 |
| 33 | Citadel Advisors LLC | 150,205 | New | 0.15% | $0 M | Nov 16, 2026 |
| 34 | Stonepine Capital Management, LLC | 150,000 | -74,989 (-33.33%) | 0.15% | $0 M | Nov 13, 2026 |
| 35 | Alps Advisors Inc | 130,424 | +34,698 (+36.25%) | 0.13% | $0 M | Nov 3, 2026 |
| 36 | Invesco Ltd. | 117,230 | +20,458 (+21.14%) | 0.11% | $0 M | Nov 12, 2026 |
| 37 | Renaissance Technologies LLC | 115,524 | +97,424 (+538.25%) | 0.11% | $0 M | Nov 12, 2026 |
| 38 | American Century Companies Inc | 113,736 | +38,941 (+52.06%) | 0.11% | $0 M | Nov 12, 2026 |
| 39 | Nuveen, LLC | 111,057 | +3,668 (+3.42%) | 0.11% | $0 M | Nov 10, 2026 |
| 40 | Prudential Financial Inc | 109,705 | +97,205 (+777.64%) | 0.11% | $0 M | Nov 16, 2026 |
| 41 | Susquehanna Portfolio Strategies, LLC | 102,223 | +14,941 (+17.12%) | 0.10% | $0 M | Nov 16, 2026 |
| 42 | XTX Topco Ltd | 100,745 | New | 0.10% | $0 M | Nov 16, 2026 |
| 43 | Rhumbline Advisers | 94,984 | -97 (-0.10%) | 0.09% | $0 M | Nov 10, 2026 |
| 44 | Point72 Asset Management, L.P. | 93,565 | +52,493 (+127.81%) | 0.09% | $0 M | Nov 16, 2026 |
| 45 | Squarepoint Ops LLC | 83,488 | +16,410 (+24.46%) | 0.08% | $0 M | Nov 9, 2026 |
| 46 | Bank Of America Corp /de/ | 70,237 | +23,376 (+49.88%) | 0.07% | $0 M | Nov 16, 2026 |
| 47 | EntryPoint Capital, LLC | 70,147 | New | 0.07% | $0 M | Nov 13, 2026 |
| 48 | Deutsche Bank AG\ | 68,976 | -9,909 (-12.56%) | 0.07% | $0 M | Nov 6, 2026 |
| 49 | Algert Global LLC | 67,553 | New | 0.07% | $0 M | Nov 17, 2026 |
| 50 | Price T Rowe Associates Inc /MD/ | 66,379 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 51 | UBS Group AG | 49,253 | -8,790 (-15.14%) | 0.05% | $0 M | Nov 10, 2026 |
| 52 | Palumbo Wealth Management LLC | 48,373 | -18,743 (-27.93%) | 0.05% | $0 M | Nov 13, 2026 |
| 53 | Citigroup Inc | 42,762 | -27,350 (-39.01%) | 0.04% | $0 M | Nov 4, 2026 |
| 54 | Jpmorgan Chase & Co | 41,369 | +7,817 (+23.30%) | 0.04% | $0 M | Nov 12, 2026 |
| 55 | Barclays PLC | 39,770 | +20,331 (+104.59%) | 0.04% | $0 M | Nov 6, 2026 |
| 56 | MetLife Investment Management, LLC | 39,235 | -8,734 (-18.21%) | 0.04% | $0 M | Nov 16, 2026 |
| 57 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 39,094 | +2,021 (+5.45%) | 0.04% | $0 M | Nov 16, 2026 |
| 58 | Vanguard Global Advisers, LLC | 33,393 | +416 (+1.26%) | 0.03% | $0 M | Nov 13, 2026 |
| 59 | Two Sigma Investments, LP | 28,488 | +9,062 (+46.65%) | 0.03% | $0 M | Nov 16, 2026 |
| 60 | Police & Firemen's Retirement System of New Jersey | 23,846 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 61 | Manufacturers Life Insurance Company, The | 23,828 | +1,745 (+7.90%) | 0.02% | $0 M | Nov 13, 2026 |
| 62 | Stifel Financial Corp | 20,291 | +1,772 (+9.57%) | 0.02% | $0 M | Nov 12, 2026 |
| 63 | BNP Paribas Financial Markets | 18,710 | +2,326 (+14.20%) | 0.02% | $0 M | Nov 12, 2026 |
| 64 | Susquehanna International Group, LLP | 17,583 | +3,533 (+25.15%) | 0.02% | $0 M | Nov 16, 2026 |
| 65 | Voya Investment Management LLC | 16,665 | +827 (+5.22%) | 0.02% | $0 M | Nov 10, 2026 |
| 66 | New York State Common Retirement Fund | 16,500 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 67 | Wells Fargo & Company/mn | 16,309 | -51,403 (-75.91%) | 0.02% | $0 M | Nov 16, 2026 |
| 68 | Alliancebernstein L.P. | 14,580 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 69 | Voleon Capital Management LP | 14,078 | New | 0.01% | $0 M | Nov 16, 2026 |
| 70 | Caxton Corp | 13,534 | -2,023 (-13.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 71 | Creative Planning | 11,308 | -2,564 (-18.48%) | 0.01% | $0 M | Nov 2, 2026 |
| 72 | ProShare Advisors LLC | 10,533 | -55 (-0.52%) | 0.01% | $0 M | Oct 29, 2026 |
| 73 | WINTON GROUP Ltd | 10,200 | -4,200 (-29.17%) | 0.01% | $0 M | Nov 12, 2026 |
| 74 | Pettinga Financial Advisors LLC | 10,000 | 0 (0.00%) | 0.01% | $0 M | Oct 13, 2026 |
| 75 | Legal & General Group Plc | 7,858 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 76 | Ameritas Investment Partners, Inc. | 7,338 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 77 | Tower Research Capital LLC (TRC) | 4,959 | -2,786 (-35.97%) | 0.00% | $0 M | Nov 16, 2026 |
| 78 | Royal Bank Of Canada | 4,612 | +2,053 (+80.23%) | 0.00% | $0 M | Nov 16, 2026 |
| 79 | PNC Financial Services Group, Inc. | 1,924 | +165 (+9.38%) | 0.00% | $0 M | Nov 6, 2026 |
| 80 | Sterling Capital Management LLC | 1,652 | +23 (+1.41%) | 0.00% | $0 M | Oct 22, 2026 |
| 81 | California State Teachers Retirement System | 1,113 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 82 | Farther Finance Advisors, LLC | 789 | New | 0.00% | $0 M | Oct 8, 2026 |
| 83 | Group One Trading LLC | 712 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 84 | Bleichroeder LP | 595 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 85 | Simplex Trading, LLC | 424 | New | 0.00% | $0 M | Nov 4, 2026 |
| 86 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 389 | New | 0.00% | $0 M | Nov 16, 2026 |
| 87 | GAMMA Investing LLC | 385 | New | 0.00% | $0 M | Oct 8, 2026 |
| 88 | Blue Trust, Inc. | 284 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 89 | Rockefeller Capital Management L.P. | 188 | +155 (+469.70%) | 0.00% | $0 M | Nov 13, 2026 |
| 90 | Osaic Holdings, Inc. | 57 | New | 0.00% | $0 M | Nov 12, 2026 |
| 91 | National Bank Of Canada /fi/ | 11 | New | 0.00% | $0 M | Nov 16, 2026 |
| 92 | SBI Securities Co., Ltd. | 11 | +2 (+22.22%) | 0.00% | $0 M | Oct 22, 2026 |
| 93 | Caitong International Asset Management Co., Ltd | 11 | -19 (-63.33%) | 0.00% | $0 M | Oct 29, 2026 |
| 94 | HighMark Wealth Management LLC | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 95 | Arax Advisory Partners | 3 | New | 0.00% | $0 M | Nov 12, 2026 |
| 96 | Root Financial Partners, LLC | 1 | New | 0.00% | $0 M | Oct 21, 2026 |
Mutual funds holding X4 Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 3.39 M | $13 M | 3.3% | 0.15% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.60 M | $12 M | 2.5% | <0.01% | +4.6% | Jun 30, 2026 |
| 🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc. | 2.31 M | $11 M | 2.3% | 3.8% | −1.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.91 M | $9 M | 1.9% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1.82 M | $8 M | 1.8% | 1.8% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 1.69 M | $7 M | 1.7% | 0.15% | no change | Jul 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 1.43 M | $6 M | 1.4% | 0.12% | −15% | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 1.34 M | $5 M | 1.3% | 0.24% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.03 M | $5 M | 1.0% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 758,220 | $4 M | 0.74% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 884,763 | $4 M | 0.87% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC | 504,600 | $2 M | 0.49% | 0.15% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 422,860 | $2 M | 0.41% | <0.01% | +4.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 271,214 | $1 M | 0.27% | 0.08% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 196,530 | $1 M | 0.19% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 167,464 | $1 M | 0.16% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 151,139 | $1 M | 0.15% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 124,251 | $1 M | 0.12% | <0.01% | −11% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 112,837 | $1 M | 0.11% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 107,389 | $0 M | 0.11% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 86,641 | $0 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 79,833 | $0 M | 0.08% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 59,100 | $0 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 66,731 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 56,741 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 46,744 | $0 M | 0.05% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 42,532 | $0 M | 0.04% | <0.01% | −13% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 42,268 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 41,980 | $0 M | 0.04% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 38,483 | $0 M | 0.04% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 29,000 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 27,197 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 30,166 | $0 M | 0.03% | <0.01% | +51% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 23,222 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 22,814 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 18,231 | $0 M | 0.02% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 17,857 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 16,839 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 12,703 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 12,524 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 14,446 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 12,192 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 10,917 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 10,068 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 11,344 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 9,468 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 8,775 | $0 M | <0.01% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 7,338 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,449 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 6,376 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,216 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 5,770 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 6,060 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,860 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 4,860 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,654 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 3,666 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,817 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,041 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,505 | $0 M | <0.01% | <0.01% | +3.6% | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 1,031 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 471 | $0 M | <0.01% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 64 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at X4 Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Adam R. CraigExecutive Chairman, Director | Buy | +4,600 | $2.583 | $12 K | 333,251 | Form 4 |
| filed | David KirskeChief Financial Officer | Sell | -11,767 | $2.860 | $34 K | 155,983 | Form 4 |
| filed | John VolponePresident | Sell | -24,576 | $4.440 | $109 K | 265,305 | Form 4 |
| filed | Adam R. CraigExecutive Chairman, Director | Sell | -47,436 | $4.440 | $211 K | 328,651 | Form 4 |
| filed | David KirskeChief Financial Officer | Sell | -8,543 | $4.260 | $36 K | 167,750 | Form 4 |
| filed | David KirskeChief Financial Officer | Sell | -16,961 | $4.290 | $73 K | 176,293 | Form 4 |
| filed | Adam R. CraigExecutive Chairman, Director | Buy | +86,206 | $2.900 | $250 K | 376,087 | Form 4 |
| filed | Adam R. CraigExecutive Chairman, Director | Grant or award | +289,881 | — | — | 289,881 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: X4 Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-30.03 reverse split ; 1-for-6 reverse split ; 1-for-3.41 reverse split ; 1-for-6 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2023 | Q3 2022 | $0.4M |
| Q4 2022 | Q4 2022 | $0M |
| Q4 2021 | Q4 2021 | $0M |
| Q4 2020 | Q4 2021 | $0M |
Trading halts
- 2025-10-24 13:39 UTC, code LUDP, resumed 13:44 UTC
- 2025-08-12 19:37 UTC, code T3, resumed 11:30 UTC
- 2025-04-25 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-01-29 19:49 UTC, code LUDP, resumed 19:54 UTC
Fails to deliver
- : 21 shares at $3.25
- : 9 shares at $3.24
- : 823 shares at $3.20
- : 2,835 shares at $2.75
- : 88 shares at $2.45
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
X4 Pharmaceuticals, Inc. scorecard#
Passes 4 of the 16 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.8×Price to book 1.8× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median9.4×Price to sales 9.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-25.8%Free cash flow is -25.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.87 vs -5.59Diluted EPS -1.87 in fiscal 2025 against -5.59 the year before (report's currency).
- ✗Net income higher than five years earlier-$79 M-$79 M in fiscal 2025 against -$62 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$79 MNet income -$79 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-247.4%-247.4% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-76.0%-76.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.15 at the end of fiscal 2025.
- ✓Debt below equity0.4×Debt to equity 0.40 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $142 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.85Z-score -0.85 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from X4 Pharmaceuticals, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -247.5% | -60.5% | |
| Net margin | -225.6% | -68.9% | |
| Return on equity | -76.0% | -61.0% | |
| Debt to equity | 0.40× | 0.26× | |
| Free cash flow margin | -243.9% | -61.5% |
4of 9on the Piotroski tests of financial strength
- Net loss of $79 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$86 million.
- More cash than debt: net cash of $142 million.
X4 Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 35+1251%100% | 2.6r2.6—100% | 0—— | 0—— | 0−100%— | 3.0—100% | 0—— | 0r3.5—— | — | — | |
| Cost of revenue | 5.8+622%16.4% | 0.8—30.7% | 0—— | 0—— | — | — | — | — | — | — | |
| Research and development | 73−10.9%207% | 82+13.4%3140% | 72+17.9%— | 61+20.6%— | 51+20.8%— | 42+39.0%1398% | 30+48.3%— | 20r31+19.2%— | 17r28−4.3%— | 18—— | |
| General and administrative | 44−29.3%124% | 62+73.3%2366% | 36+31.4%— | 27+9.4%— | 25+18.0%— | 21+18.7%698% | 18+102%— | 8.7r18+68.7%— | 5.2r8.0−20.5%— | 6.5—— | |
| Operating expenses | — | — | 108+22.8%— | 88+2.9%— | 85+35.4%— | 63+21.6%2096% | 52+77.8%— | 29r49+30.7%— | 22r36−8.6%— | 24—— | |
| Total costs and expenses | — | 39−63.8%1498% | 108+22.8%— | 88—— | — | — | — | — | — | — | |
| Operating income | −87—−247% | −36—−1400% | −108—— | −88—— | −85—— | −60—−1996% | −52—— | −29r−46—— | −22r−36—— | −24—— | |
| Interest and finance income | 4.6−20.7%13.0% | 5.8+25.9%222% | 4.6+1992%— | 0.2+2090%— | 0.0−96.3%— | 0.3−77.2%9.1% | 1.2+407%— | 0.2r0.8+269%— | 0.1r0.2—— | — | |
| Interest expense and finance costs | 8.9+1.2%25.3% | 8.8+51.8%337% | 5.8+44.7%— | 4.0+9.6%— | 3.6+35.5%— | 2.7+25.2%89.6% | 2.1+198%— | 0.7r1.0+46.9%— | 0.5r2.1−80.5%— | 2.5—— | |
| Other non-operating income (expense) | 7.7—22.0% | −0.7−111%−28.4% | 6.4—— | −6.3—— | −3.6—— | −2.1—−70.3% | −1.1—— | −4.2r2.9−1760%— | 0.3r2.3−81.5%— | 1.4—— | |
| Income before tax | −79—−225% | −37—−1428% | −101—— | −94—— | −89—— | −62—−2066% | −53—— | −33r−43—— | −22r−34—— | −23—— | |
| Income tax | 0.0−86.8%0.1% | 0.3+297%11.9% | 0.1+179%— | 0.0+64.7%— | 0.0−88.5%— | 0.1—4.9% | 0—— | 0—— | — | — | |
| Net income including minority interests | — | −37—−1440% | −101—— | −94—— | −89—— | −62—−2071% | −53—— | −33—— | −22—— | — | |
| Net income attributable to shareholders | −79—−226% | −37—−1440% | −101—— | −94—— | −89—— | −62—−2071% | −53—— | −33r−43—— | −22r−34—— | −23—— | |
| Earnings per share, basic | -1.87—— | -5.59r-0.19—— | -17.07r-0.57—— | -1.52—— | -3.99—— | -3.09—— | -4.63—— | -79.15r-3.01—— | -54.58r-16.45—— | -44.79—— | |
| Earnings per share, diluted | -1.87—— | -5.59r-0.19—— | -17.07r-0.57—— | -1.52—— | -3.99—— | -3.09—— | -4.63—— | -79.15r-3.01—— | -54.58r-16.45—— | -44.79—— | |
| Shares, weighted average (basic) | 42+531%— | 6.7r201+13.1%— | 5.9r178−90.7%— | 64r64+147%— | 26r26+28.3%— | 20—— | — | — | — | — | |
| Shares, weighted average (diluted) | 42+531%— | 6.7r201+13.1%— | 5.9r178−90.7%— | 64r64+147%— | 26r26+28.3%— | 20+74.1%— | 12+2412%— | 0.5r14+0.2%— | 0.5r2.1−10.8%— | 0.5—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 217+290%74.7% | 56−43.9%38.0% | 99−18.5%67.4% | 122+48.8%78.2% | 82+3.9%69.8% | 79−37.6%64.1% | 126+1451%78.5% | 8.1r31−69.5%81.8% | 27r77+76.0%32.8% | 15r3.0—— | |
| Receivables | 0.6−46.4%0.2% | 1.1—0.7% | 0—0.0% | — | — | — | 0—0.0% | — | — | — | |
| Inventory | — | 2.8—1.9% | 0—0.0% | — | — | — | — | — | — | — | |
| Other current assets | 3.5−36.9%1.2% | 5.6−23.4%3.8% | 7.3+25.7%5.0% | 5.8+8.7%3.7% | 5.3+45.1%4.6% | 3.7+236%3.0% | 1.1−9.0%0.7% | 1.2r1.4+246%12.1% | 0.3—0.4% | — | |
| Current assets | 262+133%90.1% | 112−8.1%76.6% | 122−5.1%82.9% | 129+46.4%82.7% | 88+5.5%75.0% | 83−35.6%67.8% | 129+1284%80.4% | 9.3r35−88.3%93.9% | 80—97.9% | — | |
| Property, plant and equipment | 0.2−76.5%0.1% | 0.8+4.2%0.5% | 0.7−32.5%0.5% | 1.1−27.1%0.7% | 1.5+22.4%1.3% | 1.2+207%1.0% | 0.4+67.2%0.3% | 0.2r0.3−42.8%2.4% | 0.4—0.5% | — | |
| Right-of-use (leased) assets | 1.4−65.3%0.5% | 4.1−28.1%2.8% | 5.7−21.8%3.8% | 7.2−17.0%4.6% | 8.7+9.4%7.4% | 8.0+306%6.5% | 2.0—1.2% | — | — | — | |
| Goodwill | 170.0%6.0% | 170.0%11.8% | 170.0%11.8% | 170.0%11.2% | 17−36.0%14.8% | 270.0%22.1% | 27—16.9% | 0—0.0% | — | — | |
| Other intangible assets | 9.3−7.5%3.2% | 10—6.8% | 0—0.0% | — | — | — | — | — | — | — | |
| Total assets | 290+98.3%100% | 146−0.6%100% | 147−5.4%100% | 156+32.8%100% | 117−4.6%100% | 123−23.5%100% | 161+1516%100% | 9.9r36−87.8%100% | 81—100% | — | |
| Accounts payable | 5.7−33.9%2.0% | 8.6−3.6%5.9% | 8.9+15.0%6.1% | 7.8+81.6%5.0% | 4.3+36.2%3.7% | 3.1+50.6%2.6% | 2.1−29.7%1.3% | 3.0r0.5+56.8%29.9% | 1.9—2.3% | — | |
| Debt due within a year | — | — | 0−100%0.0% | 1.3+65.4%0.8% | 0.8—0.7% | 0—0.0% | 0−100%0.0% | 1.7—17.0% | — | — | |
| Current liabilities | 26−21.7%8.9% | 33+43.8%22.4% | 23+2.4%15.5% | 22+59.2%14.3% | 14+17.4%12.0% | 12+26.5%9.7% | 9.4+19.5%5.9% | 7.9r5.4−26.0%79.5% | 11—13.1% | — | |
| Long-term debt | — | — | 55+68.9%37.1% | 32−2.5%20.8% | 33−0.1%28.3% | 33+65.9%27.0% | 20+141%12.4% | 8.3—83.6% | — | — | |
| Lease liabilities (non-current) | 0−100%0.0% | 1.4−46.0%1.0% | 2.6−27.5%1.8% | 3.6−24.6%2.3% | 4.8+6.5%4.1% | 4.5+134%3.6% | 1.9—1.2% | — | — | — | |
| Total liabilities | 104−16.2%35.9% | 124+29.3%84.9% | 96+17.9%65.3% | 82+54.5%52.4% | 53+5.4%45.0% | 50+59.1%40.8% | 31+45.6%19.6% | 22r14−4.1%217% | 23—27.7% | — | |
| Retained earnings | −595—−205% | −515—−352% | −478—−325% | −377—−242% | −283—−241% | −194—−158% | −132—−82.2% | −79r−135—−797% | −92—−114% | — | |
| Shareholders' equity | 186+741%64.1% | 22−56.7%15.1% | 51−31.0%34.7% | 74+15.0%47.6% | 64−11.5%55.0% | 73−43.7%59.2% | 129—80.4% | −77r22—−775% | −45r59—−54.8% | −23r−57—— | |
| Total liabilities and equity | 290+98.3%100% | 146−0.6%100% | 147−5.4%100% | 156+32.8%100% | 117−4.6%100% | 123−23.5%100% | 161+1516%100% | 9.9r36−87.8%100% | 81—100% | — | |
| Shares outstanding | 91+1495%— | 5.7r171−96.6%— | 167+37.6%— | 122+333%— | 28+72.5%— | 16+1.1%— | 16+4487%— | 0.4r15−97.5%— | 14—— | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.3+60.4%3.6% | 0.8+90.0%30.6% | 0.4−18.3%— | 0.5+2.8%— | 0.5+42.2%— | 0.4+241%11.7% | 0.10.0%— | 0.1r0.2+45.1%— | 0.1r0.2−75.1%— | 0.3—— | |
| Share-based compensation | 4.3−47.6%12.2% | 8.2−5.6%316% | 8.7+67.1%— | 5.2−15.9%— | 6.2+13.9%— | 5.4+165%181% | 2.1+170%— | 0.8r5.6+54.3%— | 0.5r0.9−23.6%— | 0.6—— | |
| Cash from operating activities | −86—−244% | −131—−5035% | −97—— | −77—— | −71—— | −59—−1961% | −48—— | −25r−41—— | −21r−28—— | −22—— | |
| Capital expenditure | 0—0.0% | −0.3—−12.5% | −0.1—— | −0.1—— | −0.6—— | −1.4—−45.4% | −0.2—— | 0r−0.0—— | −0.4r−0.0—— | −0.1—— | |
| Intangible assets bought | — | −7.0—−269% | 0—— | 0—— | — | — | — | — | — | — | |
| Cash from investing activities | 8.2−87.8%23.2% | 67—2577% | −15—— | −0.1—— | −0.6—— | −1.4−105%−45.4% | 27—— | 0r−0.0—— | −0.4r−0.0—— | −0.1—— | |
| Debt issued | — | — | — | — | — | — | — | — | 0.7+35.0%— | 0.5—— | |
| Debt repaid | 0—0.0% | 0—0.0% | −2.1—— | −0.8—— | 0—— | 0—0.0% | −9.4—— | −6.4r−4.7—— | 0r−2.3—— | −0.3—— | |
| Shares issued | 239—679% | 0−100%0.0% | 60—— | — | — | — | — | — | — | — | |
| Shares bought back | — | — | 0—— | 0—— | −2.0—— | 0—0.0% | 0—— | — | — | — | |
| Cash from financing activities | 239+1076%680% | 20−77.1%781% | 89−24.5%— | 117+57.9%— | 74+499%— | 12−91.2%413% | 141+1947%— | 6.9r−4.5−79.4%— | 33r101+84.2%— | 18—— | |
| Exchange-rate effect on cash | 0.2—0.6% | −0.2−258%−6.0% | 0.1—— | −0.1—— | −0.3−179%— | 0.4—13.4% | −0.3—— | 0r−0.3—— | 0r0.4—— | −0.1—— | |
| Change in cash | 161—460% | −44—−1684% | −23−157%— | 40+1559%— | 2.4—— | −47−140%−1579% | 120—— | −19r−46−258%— | 12r74—— | −3.7—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 16−51.5%100% | 2.8+75.0%100% | 8.8+418%100% | 2.5−91.3%100% | 2.2*+46.7%100% | 1.6r1.6+186%100% | 1.7r1.7+202%100% | 29—100% | 1.5*—100% | 0.6—100% | 0.6—100% | 0—— | 0*—— | |
| Cost of revenue | 3.1−45.7%19.0% | 0.5+46.2%18.3% | 1.6+396%18.4% | 0.6−87.3%23.9% | 0.4*+20.5%16.5% | 0.4+54.6%21.9% | 0.3+21.6%19.2% | 4.7—16.4% | 0.3*—20.1% | 0.2—40.5% | 0.3—47.6% | 0—— | 0*—— | |
| Research and development | 62−17.8%383% | 13−23.0%477% | 15−17.8%171% | 15−16.5%618% | 19*−14.7%842% | 17−9.6%1084% | 18−12.3%1080% | 19−6.8%64.3% | 22*+42.1%1447% | 19—3424% | 21—3715% | 20—— | 15*—— | |
| General and administrative | 32−37.9%195% | 9.0−22.2%322% | 8.5−10.8%96.5% | 7.0−53.6%279% | 7.4*−51.3%336% | 12−26.0%724% | 9.5−28.2%560% | 15−13.8%52.1% | 15*+52.6%1010% | 16—2796% | 13—2358% | 17—— | 9.9*—— | |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | — | 37—— | 25*—— | |
| Operating income | −80—−493% | −20—−714% | −16—−186% | −20—−812% | −24*—−1077% | −28—−1719% | −26−137%−1543% | −9.4—−32.8% | −36*—−2381% | −35—−6161% | 71—12629% | −37—— | −25*—— | |
| Interest and finance income | 7.9+105%48.4% | 1.8+102%65.0% | 2.0+198%22.5% | 2.1+105%84.2% | 2.0*+56.7%90.2% | 0.9−51.8%56.3% | 0.7−57.5%39.1% | 1.0−3.8%3.6% | 1.3*−12.3%84.5% | 1.9—334% | 1.6—278% | 1.1—— | 1.4*—— | |
| Interest expense and finance costs | 8.7−3.5%53.2% | 2.2−2.8%78.4% | 2.2−3.0%24.6% | 2.1−3.0%85.4% | 2.2*−5.1%99.4% | 2.3−6.5%141% | 2.2+2.6%131% | 2.2+17.4%7.6% | 2.3*+22.2%154% | 2.4—431% | 2.2—387% | 1.9—— | 1.9*—— | |
| Other non-operating income (expense) | −0.1−101%−0.8% | −0.2—−7.3% | 0.2−55.3%2.7% | 0.1−99.3%2.6% | −0.2*−132%−10.3% | −2.3—−146% | 0.5−97.3%31.1% | 9.8—33.9% | 0.7−88.5%46.7% | −2.2—−389% | 20—3508% | −14—— | 6.1*—— | |
| Income before tax | −81—−494% | −20—−721% | −16—−183% | −20−6505%−810% | −24*—−1088% | −30—−1865% | −26−128%−1512% | 0.3—1.1% | −40*—−2638% | −37—−6550% | 91—16137% | −52—— | −19*—— | |
| Income tax | 0.0−98.3%0.0% | 0.0—0.1% | 0.0−94.6%0.0% | 0−100%0.0% | 0*−100%0.0% | −0.0−300%−1.9% | 0.0+106%2.2% | 0.0+78.9%0.1% | 0.3*+682%17.2% | 0.0—2.7% | 0.0—3.2% | 0.0—— | 0.0*—— | |
| Net income attributable to shareholders | −81—−494% | −20—−721% | −16—−183% | −20−7278%−810% | −24*—−1088% | −30—−1863% | −26−128%−1514% | 0.3—1.0% | −40*—−2655% | −37—−6553% | 91—16134% | −52—— | −19*—— | |
| Earnings per share, basic | — | -0.16—— | -0.13—— | -0.16−500%— | — | -0.69—— | -3.47−126%— | 0.04—— | — | -5.48r-0.18—— | 13.59r0.45—— | -7.77r-0.26—— | — | |
| Earnings per share, diluted | — | -0.16—— | -0.13—— | -0.16−500%— | — | -0.69—— | -3.47−126%— | 0.04—— | — | -5.48r-0.18—— | 13.57r0.45—— | -7.77r-0.26—— | — | |
| Shares, weighted average (basic) | 127+192%— | 127+192%— | 126+1604%— | 126+1746%— | — | 43+546%— | 7.4+11.0%— | 6.8+2.6%— | — | 6.7r201—— | 6.7r200—— | 6.7r200—— | — | |
| Shares, weighted average (diluted) | 127+192%— | 127+192%— | 126+1604%— | 126+1739%— | — | 43+546%— | 7.4+10.8%— | 6.9+3.0%— | — | 6.7r201—— | 6.7r201—— | 6.7r200—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 186—80.2% | 186+167%80.2% | 195+397%77.1% | 217+439%80.3% | 217+290%74.7% | 70−28.5%42.6% | 39−73.4%37.3% | 40−33.5%31.0% | 56−43.9%38.0% | 97—54.7% | 147—69.9% | 60—53.9% | 99—67.4% | |
| Receivables | 1.5—0.6% | 1.5+65.0%0.6% | 2.0+78.8%0.8% | 1.1+119%0.4% | 0.6−46.4%0.2% | 0.9—0.5% | 1.1—1.1% | 0.5—0.4% | 1.1—0.7% | 0—0.0% | 0—0.0% | — | 0—0.0% | |
| Inventory | — | — | — | — | — | — | — | — | 2.8—1.9% | — | — | — | 0—0.0% | |
| Other current assets | 3.5—1.5% | 3.5−29.8%1.5% | 3.3−32.7%1.3% | 2.5−44.0%0.9% | 3.5−36.9%1.2% | 4.9+10.0%3.0% | 5.0−0.4%4.7% | 4.5−22.2%3.4% | 5.6−23.4%3.8% | 4.5—2.5% | 5.0—2.4% | 5.8—5.1% | 7.3—5.0% | |
| Current assets | 198—85.5% | 198+49.2%85.5% | 219+200%86.5% | 242+153%89.5% | 262+133%90.1% | 133−7.1%81.2% | 73−58.4%69.4% | 96+9.6%73.6% | 112−8.1%76.6% | 143—80.2% | 175—83.3% | 87—77.8% | 122—82.9% | |
| Property, plant and equipment | 0.1—0.0% | 0.1−73.9%0.0% | 0.1−56.3%0.0% | 0.1−70.0%0.1% | 0.2−76.5%0.1% | 0.2−73.4%0.1% | 0.3−68.6%0.2% | 0.5−34.4%0.4% | 0.8+4.2%0.5% | 0.8—0.5% | 0.8—0.4% | 0.7—0.7% | 0.7—0.5% | |
| Right-of-use (leased) assets | 0.3—0.1% | 0.3−85.1%0.1% | 0.7−75.3%0.3% | 1.0−71.7%0.4% | 1.4−65.3%0.5% | 1.8−60.3%1.1% | 2.6−45.7%2.5% | 3.7−30.6%2.8% | 4.1−28.1%2.8% | 4.5—2.5% | 4.9—2.3% | 5.3—4.7% | 5.7—3.8% | |
| Goodwill | 17—7.5% | 170.0%7.5% | 170.0%6.9% | 170.0%6.4% | 170.0%6.0% | 170.0%10.6% | 170.0%16.5% | 170.0%13.3% | 170.0%11.8% | 17—9.7% | 17—8.2% | 17—15.5% | 17—11.8% | |
| Other intangible assets | 13—5.5% | 13+35.9%5.5% | 13+36.1%5.2% | 9.1−7.6%3.4% | 9.3−7.5%3.2% | 9.4−7.4%5.8% | 9.6−7.2%9.2% | 9.8—7.5% | 10—6.8% | 10—5.7% | 10—4.9% | — | 0—0.0% | |
| Total assets | 232—100% | 232+41.7%100% | 253+141%100% | 270+108%100% | 290+98.3%100% | 164−8.2%100% | 105−50.1%100% | 130+15.9%100% | 146−0.6%100% | 178—100% | 211—100% | 112—100% | 147—100% | |
| Accounts payable | 4.9—2.1% | 4.9−3.3%2.1% | 3.9−49.0%1.6% | 5.1−54.4%1.9% | 5.7−33.9%2.0% | 5.1−41.1%3.1% | 7.7−3.5%7.3% | 11+24.4%8.5% | 8.6−3.6%5.9% | 8.6—4.8% | 8.0—3.8% | 8.9—8.0% | 8.9—6.1% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Current liabilities | 15—6.5% | 15−36.3%6.5% | 19−15.4%7.7% | 24−8.2%8.8% | 26−21.7%8.9% | 24−19.7%14.4% | 23−20.8%21.8% | 26+10.0%19.9% | 33+43.8%22.4% | 29—16.4% | 29—13.7% | 24—21.0% | 23—15.5% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | 55—37.1% | |
| Lease liabilities (non-current) | — | — | — | — | 0−100%0.0% | 0.1−94.6%0.1% | 0.8−59.8%0.8% | 1.1−52.2%0.9% | 1.4−46.0%1.0% | 1.8—1.0% | 2.0—1.0% | 2.3—2.1% | 2.6—1.8% | |
| Total liabilities | 93—40.1% | 93−8.8%40.1% | 98−3.5%38.6% | 102−4.9%37.7% | 104−16.2%35.9% | 102−14.0%62.3% | 101−12.9%96.2% | 107−3.7%82.4% | 124+29.3%84.9% | 119—66.5% | 116—55.2% | 111—99.1% | 96—65.3% | |
| Retained earnings | −651—−281% | −651—−281% | −631—−249% | −615—−227% | −595—−205% | −571—−349% | −541—−514% | −515—−396% | −515—−352% | −476—−267% | −439—−208% | −530—−472% | −478—−325% | |
| Shareholders' equity | 139—59.9% | 139+125%59.9% | 155+3815%61.4% | 168+634%62.3% | 186+741%64.1% | 62+3.4%37.7% | 4.0−95.8%3.8% | 23+2115%17.6% | 22−56.7%15.1% | 60—33.5% | 94—44.8% | 1.0—0.9% | 51—34.7% | |
| Total liabilities and equity | 232—100% | 232+41.7%100% | 253+141%100% | 270+108%100% | 290+98.3%100% | 164−8.2%100% | 105−50.1%100% | 130+15.9%100% | 146−0.6%100% | 178—100% | 211—100% | 112—100% | 147—100% | |
| Shares outstanding | 101—— | 101+301%— | 96+1107%— | 94+1529%— | 91+1495%— | 25−85.1%— | 8.0−95.3%— | 5.8−96.6%— | 5.7r171−96.6%— | 169—— | 168—— | 168—— | 167—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.8+33.7%10.9% | 0.3*+48.4%11.8% | 1.0*+181%11.3% | 0.2−53.2%8.9% | 0.2*−18.3%10.1% | 0.2*−16.5%13.9% | 0.4*+83.0%20.9% | 0.5+668%1.7% | 0.3*+340%18.2% | 0.3*—47.7% | 0.2*—34.5% | 0.1—— | 0.1*—— | |
| Share-based compensation | 11+166%69.1% | 3.5+361%125% | 3.1+313%35.0% | 2.4+365%96.5% | 2.3*+2.4%103% | 0.8−58.2%47.5% | 0.7−69.2%44.0% | 0.5−70.2%1.8% | 2.2*−12.7%148% | 1.8—325% | 2.4—431% | 1.7—— | 2.5*—— | |
| Cash from operating activities | −76—−467% | −20*—−721% | −21*—−236% | −20—−784% | −16*—−706% | −28*—−1739% | −30*—−1759% | −12—−42.9% | −33*—−2200% | −34*—−6077% | −64—−11350% | −34—— | −28*—— | |
| Capital expenditure | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.0*—−2.7% | −0.1*—−16.4% | −0.1*—−23.8% | −0.1—— | −0.0*—— | |
| Cash from investing activities | 46—283% | 11*—393% | −1.0*−104%−11.4% | 19—770% | 17*—766% | −29*—−1792% | 23*−76.1%1360% | −3.1—−10.9% | −8.6*—−575% | −16*—−2844% | 97*—17205% | −5.3—— | −4.8*—— | |
| Shares issued | — | 0*−100%0.0% | — | — | 146*—6638% | 87*—5432% | — | — | 0*−100%0.0% | 0r0*—0.0% | — | — | 51*—— | |
| Cash from financing activities | 146+57.6%896% | −0.1*−100%−4.0% | 0.1*−98.7%0.9% | 0.0—0.1% | 146*+108116%6641% | 87*—5432% | 5.6*−72.1%331% | 0—0.0% | 0.1*+39.2%9.0% | 0*—0.0% | 20*—3581% | 0—— | 0.1*—— | |
| Exchange-rate effect on cash | −0.0—−0.1% | 0.0*—0.2% | −0.0*−104%−0.1% | −0.0−128%−0.8% | 0.0*—0.1% | −0.0*−101%−0.1% | 0.1*—8.2% | 0.1—0.2% | −0.2*−292%−16.3% | 0.2*—29.5% | −0.0*—−3.2% | −0.1—— | 0.1*—— | |
| Change in cash | 116—712% | −9.3*−131%−332% | −22*—−247% | −0.4—−14.6% | 147*—6701% | 30*—1901% | −1.0*−101%−59.9% | −15—−53.6% | −42*—−2782% | −50*—−8892% | 87*—15404% | −39—— | −32*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What X4 Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- License and other revenue$29 M81%—
- Product revenue, net(total)$7 M19%+155%
Business segments
- Reportable$35 M100%+1271%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at X4 Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $6.7 M | $16.3 M | $5.6 M | $13 |
| 2024Dr. Ragan | $2.1 M | $1.4 M | $1.2 M | $74 |
| 2023Dr. Ragan | $2.0 M | $1.3 M | $1.4 M | $84 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at X4 Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 2 · Directors and officers 6 · Material agreement 6 · Agreement ended 1 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Material agreementAgreement endedNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K/A | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 8, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2025 | $85 M | Private placement after listing | $50 to $250 million | 18 | equity, options | SEC |
| May 2023 | $65 M | Private placement after listing | $50 to $250 million | 22 | equity, options | SEC |
| Jul 2022 | $56 M | Private placement after listing | $50 to $250 million | 23 | equity, options | SEC |
| Nov 2017 | $20 M | No. 5 | $10 to $50 million | 1 | equity | SEC |
| Apr 2017 | $46 M | No. 4 | $10 to $50 million | 18 | equity | SEC |
| Apr 2016 | $15 M | No. 3 | $10 to $50 million | 10 | equity, debt | SEC |
| Jul 2013 | $20 M | No. 2 | $10 to $50 million | 8 | equity | SEC |
| Jan 2011 | $10 M | No. 1 | $2 to $10 million | 7 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at X4 Pharmaceuticals, Inc.#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $340 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Executive Medical DirectorMedical Scientists, Except Epidemiologists | 1 | $340 K |
Where: Boston, MA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as X4 Pharmaceuticals, Inc.
FDA drug approvals: X4 Pharmaceuticals, Inc.#
1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2024.
| Approved | Drug | Kind |
|---|---|---|
| 2024-04-26 | Xolremdinew moleculeMavorixafor · NDA218709 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (X4 PHARMS), so they follow acquisitions
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | 43 | · | · | · | · | · | · | · | · | · | · | 43 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 50% of workforce | Restructuring planSEC 8-K | “As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million.” | Filing | |
| 43 people (30% of workforce) | Restructuring planSEC 8-K | “In connection with this shift in operational focus and strategic restructuring, the Company expects to implement a net reduction of its employee headcount by 43 employees, or appro…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How X4 Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$332 M · higher than 52% of 726
- Revenue$35 M · higher than 55% of 647
- Net margin-225.6% · higher than 25% of 408
- Revenue growth1250.4% · higher than 98% of 438
- Price / sales9.4× · lower than 45% of 339
- Price / book1.8× · lower than 61% of 534
- FCF yield-25.8% · higher than 38% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| X4 Pharmaceuticals, Inc.🇺🇸 | $332 M | — | -225.6% | +1250.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at X4 Pharmaceuticals, Inc.? Verify and update this profile — free
Show X4 Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.